IL1B and acute respiratory distress syndrome: The blockage of key inflammatory mediators, through antibody-mediated neutralisation, have been considered for SARS-CoV-2-induced ARDS, such as tumour necrosis factor (TNF)-α inhibitors and interleukin (IL)-1 inhibitors [16].